Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.
Romualdo Barroso-SousaJuliet FormanKatharine CollierZachary T WeberTejas R JammihalKatrina Z KaoEdward T RichardsonTanya E KeenanOfir CohenMichael P ManosRyan C BrennickPatrick A OttF Stephen HodiDeborah A DillonVictoria AttayaTess A O'MearaNancy U LinEliezer Van AllenScott RodigEric P WinerElizabeth A MittendorfCatherine J WuNikhil WagleDaniel G StoverSachet A ShuklaSara M TolaneyPublished in: JCO precision oncology (2022)
This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.